Lv21
150 积分 2023-04-18 加入
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
2天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
4天前
已完结
The antibody–drug conjugate landscape
13天前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
14天前
已完结
Targeting the MET pathway for potential treatment of NSCLC
14天前
已完结
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
17天前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
17天前
已完结
Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
17天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
18天前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
19天前
已完结
皖公网安备34019202002308
